459 related articles for article (PubMed ID: 28392512)
1. Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.
Nakamura M; Yamada N; Ito M
J Atheroscler Thromb; 2017 Jun; 24(6):560-565. PubMed ID: 28392512
[TBL] [Abstract][Full Text] [Related]
2. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.
Badreldin H
J Thromb Thrombolysis; 2018 Jul; 46(1):16-21. PubMed ID: 29626281
[TBL] [Abstract][Full Text] [Related]
3. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
4. Drug Treatment of Venous Thromboembolism in the Elderly.
Boey JP; Gallus A
Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
[TBL] [Abstract][Full Text] [Related]
5. All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
Roetker NS; Lutsey PL; Zakai NA; Alonso A; Adam TJ; MacLehose RF
Thromb Haemost; 2018 Sep; 118(9):1637-1645. PubMed ID: 30103250
[TBL] [Abstract][Full Text] [Related]
6. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
7. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Imberti D; Mastroiacovo D
Intern Emerg Med; 2017 Aug; 12(5):561-563. PubMed ID: 28647891
[TBL] [Abstract][Full Text] [Related]
8. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
9. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Weitz JI; Jaffer IH
Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
[TBL] [Abstract][Full Text] [Related]
11. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Proietti M; Lip GY
Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
[TBL] [Abstract][Full Text] [Related]
12. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulants: What is new and what is the standard?
Lesko LJ
Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
[TBL] [Abstract][Full Text] [Related]
14. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
Medina A; Raskob G; Ageno W; Cohen AT; Brekelmans MPA; Chen CZ; Grosso MA; Mercuri MF; Segers A; Verhamme P; Vanassche T; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Thromb Haemost; 2017 Dec; 117(12):2406-2414. PubMed ID: 29212128
[TBL] [Abstract][Full Text] [Related]
15. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
Imberti D; Pomero F; Benedetti R; Fenoglio L
Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399
[TBL] [Abstract][Full Text] [Related]
16. New anticoagulants for the treatment of venous thromboembolism.
Fernandes CJ; Alves Júnior JL; Gavilanes F; Prada LF; Morinaga LK; Souza R
J Bras Pneumol; 2016 Apr; 42(2):146-54. PubMed ID: 27167437
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
18. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
Vanassche T; Vandenbriele C; Peerlinck K; Verhamme P
Expert Opin Pharmacother; 2015 Apr; 16(5):645-58. PubMed ID: 25554350
[TBL] [Abstract][Full Text] [Related]
20. Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency.
Yagi S; Kagawa K; Fujimoto E; Sata M
J Med Invest; 2019; 66(1.2):182-184. PubMed ID: 31064935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]